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Abstract. Fourteen male patients with mild to moderate 
essential hypertension have been studied with regard to 
plasma renin activity (PRA) after acute and prolonged /?- 
adrenergic blockade with propranolol. Initial PRA was 
determined after four weeks of placebo treatment. Before 
propranolol was given PRA rose in response to 10 min of 
45" head-up tilt from 151.7 ng/100 ml/h to 248.7 ng/100 ml/h 
( p <  0.01). After acute administration of propranolol 0.22 
mg/kg b.wt. i.v. and following repeated tilt for 10 min 
PRA only rose to 204.7 ng/100 ml/h (n.s.). Following four 
weeks of oral propranolol treatment at 160-320 mg daily 
PRA after tilt was 39.0 ng/100 ml/h. Thus a significant 
reduction (of PRA had taken place (p<0.005) to a level 
constitutial: only 15 % of the initial PRA after tilt. 
The reduction of blood pressure (BP) after four weeks of 
propranolol treatment was also significant. Diastolic BP was 
reduced by 19 mmHg(p< 0.001). The changes in BP and tilted 
PRA were not significantly correlated ( r =  0.449, p <  0.10). 
These results indicate that propranolol causes a marked 
reduction of PRA in addition to its hypotensive effect. How- 
ever, this does not necessarily imply that there is a direct 
causal relationship between the effect of propranolol on PRA 
and its effect on BP. 
Usually, renin is not elevated in patients with non- 
malignant essential hypertension (7, 12, 29) and 
aldosterone secretion is normal (7, 19). On the other 
hand, elevated renin levels and increased aldosterone 
secretion practically always occur in malignant 
hypertension (16, 17, 20). Already in 1960 Laragh 
et a]. suggested that the vascular damage seen in 
malignant hypertension was related to elevated levels 
of angiotensin (16, 17). Later animal studies have 
shown that excess renin/angiotensin may cause vas- 
cular lesions of the same appearance as those seen 
in malignant hypertension (5 ,  8, 9, 22). 
Recently Laragh's group presented observations 
on 219 hypertensive patients followed for 10 years, 
' Present address: Department of Internal Medicine I, Sahl- 
gren's Hospital, University of Goteborg, Goteborg, Sweden. 
which indicated that low plasma renin was associated 
with a reduced risk of cardiovascular complications 
such as stroke and myocardial infarction (2). Others 
do not support this view (6). 
Based on observations by Laragh and coworkers 
(2), it would be logical to use antihypertensive 
therapy that not only reduces blood pressure (BP) 
but also lowers renin actively. Several of the anti- 
hypertensive drugs have been studied with regard 
to their effect on plasma renin activity (PRA). 
Thus diuretics ( 1 ,  28), hydralazine (21), diazoxide 
(15) and sodium nitroprusside (14) have been shown 
to cause elevations of PRA, while drugs with 
adrenergic inhibitory effects may cause mild to 
moderate reductions of PRA. This has been de- 
monstrated e.g. for methyldopa (23), clonidine (13, 
24), phentolamine (30), propranolol (30) and alpre- 
nolol (4). 
As propranolol, at least in acute experiments, 
seems to be quite eflective in reducing PRA (3) and 
as the experience with propranolol in hypertension 
has been encouraging (11, 26, 31) the present study 
was designed to study the effect on PRA of acute 
and chronic /?-adrenergic blockade with propranolol 
in patients with essential hypertension. 
MATERIAL 
Fourteen male patients, 11 Caucasian, 3 Black, with mild to 
moderate essential hypertension were studied. Their average 
age was 45 years (range 27-66). Further details on the patients 
are recorded in Table I. Secondary causes for hypertension 
were excluded (physical examination, rapid sequence uro- 
grams or renal arteriograms, serum electrolytes and urinary 
catecholamines and aldosterone). Finally, patients with a 
history of bronchial asthma or  cardiac failure were not in- 
cluded in the study. 
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Table I. Patient information Blood pressure measurements 
Office BPs were recorded by the same two nurses through- 
out the study. Their correlation was checked frequently by 
simultaneous readings using a “Y” connection. Readings 
were always at the same time of day in the recumbent position 
after 15 min rest in a quiet air-conditioned room. Phase V 




Pat. Age Eye (mg1100 BPd 
no. (y.) Racea groundsb ml) LVHC (mmHg) 
1 5 O C  I 
2 50 B I1 
3 5 5 B  I 
4 5 3 c  I 
5 6 6 C  I 
6 40 C I1 
7 2 7 B  0 
8 5 2 C  I 
9 49 c I1 
10 45 c I1 
1 1 4 4 c  I 
12 41 C I1 
13 43 C I1 





























a C = Caucasian, B = Black. 
Keith, Wagener and Barker classification. 
Left ventricular hypertrophy in ECG or chest X-ray. 
Measured after I S  min recumbency in the clinic following 
4 weeks of placebo treatment. 
METHODS 
After informed consent was obtained, all patients were given 
placebo as the only treatment for four weeks. They were 
then admitted to the Clinical Research Unit for four days. 
During these days baseline laboratory studies were per- 
formed. A no-added-salt diet (< 180 mEq Na daily) was 
introduced in order to avoid excessive salt intake and the 
patients were instructed daily by a dietician regarding the 
continuation of this diet following discharge from the 
hospital. 
On the morning of the fourth day the initial samples for 
PRA determinations were drawn. A catheter was placed in 
the left brachial artery with the patient in the resting recum- 
bent position. After approximately 45 min of rest the first 
blood sample was drawn. The patients were then tilted to a 
45” head-up position for 10 min and a second blood sample 
was drawn. 
After recumbency had been regained for a period of 45 
min, propranolol was administered i.v. 0.22 mg/kg b.wt. 
Following a repeated 10-min period of tilt a third blood 
sample was drawn. 
The patients were then discharged with propranolol orally 
40 mg four times daily. They were advised to continue the 
no-added-salt diet. After two weeks propranolol was either 
increased to 80 mg four times daily or kept unchanged (if a 
diastolic BP reduction of I5 mmHg or more was recorded). 
The average daily dosage of propranolol during weeks three 
and four was 250 mg. 
The fourth sample for PRA determination was collected 
after four weeks of oral propranolol treatment using the same 
set-up and under identical conditions as during the initial 
sampling. The fourth arterial sample was drawn after 10 
min of tilt. 
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Analysis of plasma renin activity 
For each sample 10 ml arterial blood was collected in a pre- 
chilled tube containing approximately 10 mg EDTA-Na. 
The tube was immediately placed in ice and centrifuged with- 
in 20 min in a refrigerated centrifuge to recover the plasma. 
The plasma samples were then frozen and stored until all 
samples were collected. For analysis a radioimmunoassay 
technique was used (10, 27) by which PRA is determined 
by measuring the generated angiotensin I (SchwartzIMann, 
Orangeburg, N.Y.). Duplicate analyses were made of all 
specimens and the results were compared to a standard curve 
obtained from standard solutions of angiotensin I. Non- 
specific activity was determined in specimen no. 1 and sub- 
tracted from specimen nos. 1-3 and again determined and 
subtracted from specimen no. 4. The error of duplicate 
determinations varied between 4.2 % and 7.9 %. 
Urinary sodium excretion 
A 24-hour urine collection, ending on the morning of the 
fourth day, was made for determination of sodium excretion. 
Assessment of B-adrenergic blockade 
Infusion of i.v. isoproterenol, 3 ,ug/min for 3 min, was used 
for estimation of the degree of B-adrenergic blockade. The 
change of heart rate was calculated from a continuous ECG 
tracing. This test was performed in all patients in the initial 
untreated state and was repeated after acute i.v. as well as 
after chronic oral administration of propranolol. 
RESULTS 
Table I1 presents the individual results regarding 
PRA in the initial untreated state and after acute 
and chronic B-adrenergic blockade with propranolol 
as well as sodium excretion and change of diastolic 
pressure. The average resting PRA was 151.7 ng/100 
ml/h and rose to 248.7 ng/100 ml/h after 10 min of 
tilt (p < 0.01). Renewed tilt after i.v. propranolol 
produced a smaller increase of PRA to 204.7 ng/100 
ml/h (n.s.). 
After four weeks of oral propranolol, PRA after 
10 min of tilt was 39.0 ng/100 ml/h. This is signifi- 
cantly lower than both the initial recumbent PRA 
(p < 0.005) and the initial tilted PRA ( p  < 0.005) 
(Fig. 1). Expressed as % of the corresponding ini- 
tial tilted PRA the level after four weeks of oral 
propranolol was reduced by 85 %. 
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Table 11. Plasma renin activity (ng/IOO mllh), sodium excretion (mEql24 h) and blood pressure reduction 
(mmHg) 
Urinary PRA rest PRA tilt PRA tilt PRA tilt A Diastolic 


































40.3 59.4 27.6 14.0 
228.2 434.0 318.0 89.2 
54.4 149.0 68.9 12.4 
443.4 709.3 722.9 20.4 
48.8 52.7 N.A. 10.7 
461.3 875.6 739.6 93.4 
45.4 68.5 32.6 38.1 
113.3 135.9 60.9 16.5 
191.9 146.4 93.0 6.9 
125.4 151.4 76.2 39.7 
51.7 82.4 49.7 7.9 
76.5 148.4 142.5 90.1 
204.7 406.5 304.7 104.4 
37.9 62.2 24.9 1.7 
151.7 248.7 204.7 39.0 
& 38.2 +_ 69.8 70.1 f 10.1 
I- p < 0.01 -1 
1- n.s. I 
I I p < 0.005 _______ 
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a Propranolol 0.22 mg/kg. * Propranolol for four weeks, 160-320 mg daily. 
N.A. =not available. 
Change after four weeks of oral propranolol treatment. 
Recumbent resting BP also fell in all patients as 
can be seen in Table 11. The average drop of diastolic 
BP was 19 mmHg ( p  <0.001). 
The change of PRA from the initial tilted position 
to tilt after four weeks of oral propranolol was not 
significantly correlated to the reduction of diastolic 
BP (r = 0.449, p < 0.10). 
That clinically significant /?-adrenergic blockade 
was obtained both after i.v. and oral propranolol is 
illustrated by the effect of isoproterenol infusions. 
During placebo treatment the heart rate rose from 
73 to 112 beatslmin (p<O.OOl). After i.v. propra- 
nolol repeated infusion of isoproterenol increased 
heart rate from 66 to 67 beats/min and following 
four weeks of oral propranolol isoproterenol infusion 
increased the heart rate from 57 to 62 beats/min. 
DISCUSSION 
It has previously been demonstrated that acute 
administration of propranolol can prevent or reduce 
an expected rise of PRA in response to upright 
posture (30). On the other hand Castenfors et al. 
(4), using chronic administration of alprenolol to- 
gether with chlorthalidone, found that although 
PRA was reduced both in the recumbent and erect 
position the orthostatic increase of PRA was not 
abolished. We cannot exclude the possibility of a 
small increase of PRA due to tilt after acute or 
prolonged /?-blockade as recumbent PRA was not 
measured after propranolol, but clearly any such 
increase must have been minute. 
The effects of chronic oral administration of pro- 
pranolol are quite striking, causing a marked reduc- 
tion of PRA. Thus, comparing PRA after tilt in 
the untreated state and after oral propranolol it 
can be seen that PRA after chronic p-adrenergic 
blockade is only 15% of the initial level. Absolute 
final values in individual patients were either low 
or exceptionally low. The poor correlation between 
reduction of PRA and reduction of BP may be due 
to the fact that, although PRA fell drastically in 
all patients, the BP change was variable within the 
group. For this reason we cannot support the hypo- 
thesis of Buhler et al. (3) that induced change in 
PRA is a primary factor underlying the antihyper- 
tensive effect of /?-adrenergic blockade. 
It should be pointed out, though, that a direct 
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Fig. 1. PRA in 14 patients with 
essential hypertension. Placebo 
= measurements after 4 weeks 
of placebo treatment. Recum- 
bent = horizontal rest for at 
least 45 min. Tilt = 45” head-up 
tilt for 10 min. Acute Pro- 
pranolol= 0.22 mg/kg b.wt. 
i.v. Chronic Propranolol= oral 
0 . treatment for 4 weeks with 160-320 mg daily. 
PRAafter tilt during placebo 
is significantly higher than 
in the recumbent position 
- (~‘0.01). PRA after chronic 
propranolol is significantly 
lower than after placebo both 
0 when compared to the re- 
cumbent value ( ~ ‘ 0 . 0 0 5 )  and 
the tilted value ( p  < 0.005) 
0 
0 - 
0 h - 
0 b 
* 
M& I (paired r-test). 
i. r I. 
Rev urnbent Tilt Tlll Tlll 
Placebo Propranolol 
A< utr Cll,<,l,i, 
comparison with the results of Buhler et al. is not 
possible as different methods were used for analysing 
PRA. Furthermore, our conclusions are based on 
stimulated (tilted) PRA and confined to patients 
with mild essential hypertension. Likewise, although 
low PRA hypertensives as a group did not respond 
as well to propranolol as those with normal PRA, 
the variability of this phenomenon was such that 
we found it to be statistically insignificant. Finally, 
the dosage of propranolol was almost twice as high 
in the present study in comparison with the study 
of Buhler et al. Our interpretation of these results 
is tempered by the fact that the number of patients 
in this study was relatively small and that none had 
renovascular hypertension or a remarkably high 
initial PRA. 
The rapid changes of PRA following change of 
posture that were observed in the present study 
confirm previous results by others (25). Finally, 
sodium excretion was not studied at the end of four 
weeks of propranolol therapy. However, as the 
patients were instructed by a dietician to maintain 
a “normal” diet and to avoid excess salt intake, it is 
not logical to assume that the observed drastic 
changes of PRA were significantly influenced by 
possible minor variations of salt intake. 
Regardless of its effect on BP, it is clear that 
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chronic administration of propranolol induces a low 
renin state. The clinical importance of this finding, 
i.e. its relation to the potential reduction of cardio- 
vascular complications to hypertension (2), deserves 
further investigation. 
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